Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Clinical Trials Program
LICR believes that clinical research in cancer cannot be undertaken as simply product development, but rather requires a systematic, academic approach to develop rational therapeutic strategies in the only setting that really counts – the cancer patient. LICR is one of very few academic organizations, anywhere in the world, that produces its own regulatory-standard therapeutic study agents, and plans, conducts, administers, and sponsors its own clinical trials. More »
News
Researchers from the J. Craig Venter Institute (JCVI) and the Ludwig Institute for Cancer Research (LICR) have uncovered new genomic alterations that lead to gene fusions in a breast cancer cell line by using 454 Life Sciences sequencing technology.
Investigators from the Ludwig Institute for Cancer Research (LICR) Melbourne Center reported today in the journal The Prostate that a potential new reagent could treat prostate tumors with greater specificity and reduced toxicity than many currently used therapies.